Evidence map›Paper›PMID 29207896›Full record

ReviewExpert opinion on therapeutic targets2018

Rho GTPase effectors and NAD metabolism in cancer immune suppression.

Mahmoud Chaker, Audrey Minden, Suzie Chen, Robert H Weiss, Eduardo N Chini, Amit Mahipal, Asfar S Azmi

Open access · greenAbstract readReview
In one paragraph

Review in Expert opinion on therapeutic targets, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Mahmoud Chakera Department of Oncology , Wayne State University School of Medicine, Karmanos Cancer Institute , Detroit , MI , USA.
Audrey Mindenb Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology , Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey , Piscataway , NJ , USA.
Suzie Chenb Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology , Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey , Piscataway , NJ , USA.
Robert H Weissc Division of Nephrology, Department of Internal Medicine , University of California , Davis , CA , USA.
Eduardo N Chinif Signal Transduction Laboratory, Kogod Aging Center, Department of Anesthesiology , Oncology Research, GI Signaling Center, Mayo Clinic College of Medicine , Rochester , MN , USA.
Amit Mahipalf Signal Transduction Laboratory, Kogod Aging Center, Department of Anesthesiology , Oncology Research, GI Signaling Center, Mayo Clinic College of Medicine , Rochester , MN , USA.
Asfar S Azmia Department of Oncology , Wayne State University School of Medicine, Karmanos Cancer Institute , Detroit , MI , USA.
Mayo Clinic · USRutgers, The State University of New Jersey · USThe Barbara Ann Karmanos Cancer Institute · USUniversity of California, Davis · US

Funding

Tissue CoreP50CA102701 · NCI · MAYO CLINIC ROCHESTER · PI PETERSEN, GLORIA M. · 2004 to 2018
$32.7M
Targeting PAK4 for Overcoming Drug Resistance in Pancreatic CancerR21CA188818 · NCI · WAYNE STATE UNIVERSITY · PI AZMI, ASFAR S, MOHAMMAD, RAMZI M. · 2015 to 2016
$366k
NCI NIH HHS P50 CA102701NCI NIH HHS R21 CA188818
6 · The paper itself

Abstract

introductionSustained proliferative signaling and de-regulated cellular bioenergetics are two of the chief hallmarks of cancer. Alterations in the Ras pathway and its downstream effectors are among the major drivers for uncontrolled cell growth in many cancers. The GTPases are one of the signaling molecules that activate crucial signal transducing pathways downstream of Ras through several effector proteins. The GTPases (GTP bound) interact with several effectors and modulate a number of different biological pathways including those that regulate cytoskeleton, cellular motility, cytokinesis, proliferation, apoptosis, transcription and nuclear signaling. Similarly, the altered glycolytic pathway, the so-called 'Warburg effect', rewires tumor cell metabolism to support the biosynthetic requirements of uncontrolled proliferation. There exists strong evidence for the critical role of the glycolytic pathway's rate limiting enzymes in promoting immunosuppression. Areas covered: We review the emerging roles of GTPase effector proteins particularly the p21 activated kinase 4 (PAK4) and nicotinamide biosynthetic pathway enzyme nicotinamide phosphoribosyltransferase (NAMPT) as signaling molecules in immune surveillance and the immune response. Expert opinion: In this expert opinion article we highlight the recent information on the role of GTPases and the metabolic enzymes on the immune microenvironment and propose some unique immune therapeutic opportunities.

Indexed as

AnimalsHumansImmunotherapyNADNeoplasmsrho GTP-Binding ProteinsSignal TransductionTumor MicroenvironmentNADrho GTP-Binding ProteinsGTPaseimmune checkpointNADNAMPTNAMPT inhibitorNAPRTP21 activated kinasesPAK4PAK4 inhibitorPD-1PD-L1Ras

Identifiers

PMID29207896
PMCPMC6056002
OpenAlexW2771637744

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.